The effects of the acetylcholinesterase inhibitor ENA713 and the M1 agonist AF150(S) on apolipoprotein E deficient mice

Journal of Physiology Paris

Volumn 92, Issue 3-4, 1998, Pages 299-303

  Chapman, Shira ^a   Fisher, Abraham ^b   Weinstock, Marta ^c   Brandies, Rachel ^b   Shohami, Esther ^c   Michaelson, Daniel M ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH   (Israel)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYLPIPERIDINE 4 SPIRO (2' METHYLTHIAZOLINE); ACETYLCHOLINESTERASE; APOLIPOPROTEIN E; BRAIN ENZYME; CHOLINESTERASE INHIBITOR; MUSCARINIC M1 RECEPTOR AGONIST; RIVASTIGMINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BRAIN CORTEX; COGNITION; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; HIPPOCAMPUS; HYPERLIPOPROTEINEMIA TYPE 3; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; SPATIAL MEMORY; SUBCUTANEOUS DRUG ADMINISTRATION; WORKING MEMORY;

EID: 0032105415     PISSN: 09284257     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0928-4257(98)80037-5     Document Type: Conference Paper

References (16)

1. [1] Chapman S., Michaelson D.M., Specific neurochemical derangements of brain projecting neurons in apolipoprotein E-deficient mice, J. Neurochem. 70 (1998) 708-714.
2. [2] Enz A., Amstutz R., Hoffman A., Gmelin G., Kelly P.H., Pharmacological properties of the preferentially centrally-acting acetylcholinesterase inhibitor SDZENA713, in: Kewitz H., Thompson T., Bickel U (Eds.), Pharmacological interventions on central cholinergic mechanisms in senile dementia, Zuckschwerdt, Munich, 1989, pp. 271-277.
3. 1 selective signalling neurotrophic effects and restore AF64A cognitive deficits in rats, Soc. Neurosci. Abstr. 19 (1993) 1767.
4. [4] Fisher A., Muscarinic agonists for the treatment of Alzheimer's disease: progress and perspectives, Exp. Opin. Invest. Drugs. 6 (1997) 1395-1411.
5. 1 muscarinic agonist treatment reverses cognitive and cholinergic impairments of apolipoprotein E-deficient mice, J. Neurochem. (1998), in press.
6. [6] Gordon I., Grauer E., Genis I., Sehayek E., Michaelson D.M., Memory deficits and cholinergic impairments in apolipoprotein E-deficient mice, Neurosci. Lett. 199 (1995) 1-4.
7. [7] Giacobini E., New trends in cholinergic therapy for Alzheimer's disease: nicotinic agonist or cholinesterase inhibitors, Progr. Brain Res. 109 (1996) 311-323.
8. [8] Karnovsky M.J., Roots L.A., A direct cloning thiocholine method for cholinesterases, J Histochem. Cytochem. 121 (1964) 219-222.
9. [9] Plump A.S., Smith J.D., Hayek T., Aalto-Setala K., Walsh A., Vertuyft J.G., Rubin E.M., Breslaw J.L., Severe hypercholesterolemia and atherosclerosis in apoliprotein E-deficient mice created in homologous recombination in E5 cells, Cell 16 (1992) 343-353.
10. [10] Poirier J., Delisle M.-C., Quirion R., Aubert I., Farlow M., Lahiri D., Hsui S., Bertrand P., Nalbantoglu J., Gilfir B.M., Gauthier S., Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer's disease, Proc. Natl. Acad. Sci. USA 92 (1995) 12260-12264.
11. [11] Roses A.D., Apolipoprotein E effects on the rate of Alzheimer's disease expression in beta-amyloid burden is a secondary consequence dependent on apoE genotype and duration of disease, J. Neuropathol. Exp. Neurol. 53 (1994) 429-431.
12. [12] Tanaka K., Ogawa N., Asanuma M., Kondo Y., Mori A., Chronic administration of acetylcholinesterase inhibitor in the senescent rat brain, Neurobiol. Aging. 15: (1994) 721-725.
13. [13] Tanaka K., Ogawa N., Mizukawa K., Asanuma M., Kondo Y. Nishibayashi S., Mori A., Acetylcholinesterase inhibitor ENA-713 protects against ischemia-induced decrease in pre-and postsynaptic cholinergic indices in the gerbil brain following transient ischemia, Neurochem. Res. 19 (1994) 117-122.
14. [14] Von der Kammer H., Albrecht C., Mayhaus M., Kitsch R.M., Identification of neurotransmitter-induced genes: novel targets for the molecular pharmacology of Alzheimer's disease, in: Proceedings of the 5th International Geneva/Sprigfield Symposium on Advances in Alzheimer's Therapy, 1998, 116 p.
15. [15] Weinstock M., Razin M., Chorev M., Tashma Z., Pharmacological activity of novel acetylcholinesterase agents of potential use in the treatment of Alzheimer's disease, in: Fisher A., Hanin I., Lachman C., (Eds.), Advances in Behavioral Biology, Plenum Press, 1986, pp. 539-551.
16. [16] Weinstock M., Razin M., Chorev M., Enz A., Pharmacological evaluation of phenyl-carbamates as CNS-selective acetylcholinesterase inhibitors, J. Neural. Transm. Suppl. 43 (1994) 219-225.